All News

CAPS is caused by mutations in NLRP3, a component of the inflammasome. It is thought that NLRP3 mutations lead to the uncontrolled production of the inflammatory cytokine IL-1b.

Jonathan Hausmann MD hausmannMD ( View Tweet)

Patients with more severe #CAPS phenotypes may develop hearing loss, amyloidosis, aseptic meningitis, intellectual impairment, or #arthritis.

Jonathan Hausmann MD hausmannMD ( View Tweet)

Holy Molly! TNFi (etanercept, adalimumab, infliximab, or golimumab) completely prevented stokes in patients with DADA2. #ACR19 @RheumNow

Jonathan Hausmann MD hausmannMD ( View Tweet)

"I usually do not" give methotrexate to men with RA who are trying to conceive. Dr. Bathon. "But methotrexate is in serum for brief periods, unlikely to affect semen, unlikely to affect pregnancy." Dr. Bykerk #ACR19 @RheumNow

Jonathan Hausmann MD hausmannMD ( View Tweet)

https://t.co/Zdx0syodMK

Jonathan Hausmann MD hausmannMD ( View Tweet)
Awesome to meet new people from across the globe, catch up with old friends, and discuss why #ACR20 should have abundant free food! https://t.co/lEdYZM9BHB

Links:

Jonathan Hausmann MD hausmannMD ( View Tweet)

However, 15-30% of patients with acute pericarditis develop recurrent pericarditis

Jonathan Hausmann MD hausmannMD ( View Tweet)

Recurrent pericarditis (RP) is the recurrence of pericarditis after a more than 4-6 week symptom-free period. RP is typically treated with steroids, colchicine, NSAIDs. Nevertheless, RP is associated with a high burden of disease and there is an unmet need for better treatment.

Jonathan Hausmann MD hausmannMD ( View Tweet)

The highlight of the last day of #ACR19 is the Rheumatology Roundup Highlights #ACRBest by Drs. John Cush @RheumNow and Arthur Kavanaugh @ACRheum always worth attending with great take home messages #rheum https://t.co/eMdvc2byKG

Dr. Antoni Chan synovialjoints ( View Tweet)
Hope to have many more interdisciplinary discussions re. irAEs #ACR19 @LCalabreseDO @CCalabreseDO @EladSharonMD @DrJNaidoo @UmaThanaMD @lexmeara @drdavidliew https://t.co/8KDorKW2WJ

Links:

Laura Cappelli cappelliMD ( View Tweet)

Great ACR 2019. We weathered the weather #ACR @RheumNow https://t.co/lCKxADudRf
Janet Pope Janetbirdope ( View Tweet)
Different centres have different yields from temporal artery biopsy independent of biopsy length #ACR19 @RheumNow Abs 2685 https://t.co/Gqy9sY4OrM
Philip Robinson philipcrobinson ( View Tweet)
Just took few pictures during social media gathering yesterday at #ACR19. It was so nice to meet everyone. Thanks to @psufka for organizing and it was nice to meet the man behind the legend! @Drbeckyg @maio_danila https://t.co/lSpPz0V4ng
Angelo Gaffo ALGaffoRheumMD ( View Tweet)
Therapeutic approach to skin in #Scleroderma #ACR19 https://t.co/ZV8J5Z0wum
Juan Ovalles, MD, PhD DrJuanOvalles ( View Tweet)
Couldn’t be explained better https://t.co/m7qmeWCLnl

Links:

Jose Campos JoseCamposMD ( View Tweet)

Myositis Treatment Pearls - Optimize drug dose and allow adequate time to reach effectiveness - Steroids NOT always necessary - Steroids and IVIG are the fastest acting agents - Reasons for admission: dysphagia and SOB

Kanika Monga, MD DrKanikaMonga ( View Tweet)

Primary care providers - take a look at these new gout guidelines. They're very straightforward, and your patients will do much better than if you follow the ACP guidelines. #ACR19 https://t.co/BIGLj6GKRe

Links:

Dr. Paul Sufka psufka ( View Tweet)

Hello #ACR19. Are you still confused 😲 about the #pathways of #JAK-inhibitors and #Interferon-blocking strategies in #Lupus? Check up this refresher slide showing what these #SLE #treatments target!! 🎯 https://t.co/ZNnJTkz4nK
Laurent ARNAUD Lupusreference ( View Tweet)
That’s a wrap on #ACR2019 ! Check out @RheumNow for meeting coverage, and see you next year in DC! @LCalabreseDO #cleclinicrheum https://t.co/sx2M5sD6pU
Cassandra Calabrese CCalabreseDO ( View Tweet)
Never thought I'd say it. ACR in beautiful Atlanta. Kind of grows on you. #ACR #ACR19 @RheumNow https://t.co/YJOi5lEQei
Janet Pope Janetbirdope ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×